Svn53 67 M57 Klh Peptide

SurVaxM is a therapeutic cancer vaccine from MimiVax that trains the immune system to attack tumor cells expressing survivin, a protein cancer cells hijack to avoid dying. The lead Phase 2a trial (NCT02455557) tested SurVaxM alongside standard temozolomide chemoradiation in 64 patients with newly diagnosed glioblastoma, an aggressive brain cancer with a median overall survival of roughly 15 months on temozolomide alone and about 21 months when tumor treating fields are added (the contemporary standard of care) [1][2][9][12]. Roswell Park Comprehensive Cancer Center, where the vaccine was invented, ran the trial. MimiVax holds commercial rights. Published Phase 2a results reported median progression-free survival of 11.4 months and median overall survival of 25.9 months in an HLA-A*02:01-positive cohort [3]. A randomized, placebo-controlled Phase 2b confirmatory trial (SURVIVE, NCT05163080, targeting ~247 patients across 11 sites) has reached data cutoff, with topline results pending [13]. The result matters because glioblastoma has resisted almost every immunotherapy approach tried against it, including PD-1 blockade with nivolumab and pembrolizumab. If SURVIVE confirms a survival benefit, SurVaxM would join DCVax-L as one of very few active immunotherapies with randomized evidence in GBM.

SurVaxM is a novel investigational biologic with no approvals anywhere. MimiVax has publicly stated FDA orphan drug and fast track designations for glioblastoma, which reduce regulatory friction but do not lower the evidentiary bar for approval [4]. The Phase 2a study in newly diagnosed GBM (NCT02455557) enrolled 64 patients (of 66 originally targeted), restricted to HLA-A*02:01-positive individuals, and was published in the Journal of Clinical Oncology in 2023 [2][3]. A randomized, placebo-controlled Phase 2b confirmatory trial, SURVIVE (NCT05163080), was launched in 2022 to enroll approximately 247 patients across 11 sites; MimiVax announced in 2024 that data cutoff had been reached, with topline results pending as of mid-2026 [13]. A separate Phase 2 trial combining SurVaxM with Merck's pembrolizumab in recurrent GBM (NCT04013672) enrolled 41 patients and has completed, with data reported at oncology meetings [5]. MimiVax has also run smaller Phase 1 studies in newly diagnosed multiple myeloma on lenalidomide maintenance (NCT02334865) and metastatic neuroendocrine tumors (NCT03879694) to test the vaccine outside brain cancer [6][7]. MimiVax is privately held, and no recent runway or financing disclosures could be verified from primary sources; execution of any Phase 3 registration trial would likely require partnership with a larger sponsor or non-dilutive capital.

Survivin (gene BIRC5) is a protein tumor cells depend on for two things: staying alive and dividing. It blocks apoptosis, the built-in self-destruct program healthy cells use to eliminate themselves when damaged, and it helps organize chromosome separation during cell division. What makes survivin an attractive drug target is a quirk of expression. Nearly every human tumor overexpresses it (glioblastoma, lung, breast, colon, myeloma), while most normal adult tissues make almost none [8]. That gives an immunotherapy a real shot at hitting cancer cells without collateral damage to normal tissue. SurVaxM is a 15-amino-acid piece of the survivin protein (residues 53 through 67) engineered with a single substitution at position 57 (the 'M57' in the name) to bind more tightly to HLA-A*02:01. HLA molecules are the display surface immune cells scan for foreign or abnormal peptides. There are dozens of HLA variants across the human population, and any given peptide vaccine only works in patients carrying compatible ones (this is called MHC class I restriction). HLA-A*02:01 is the most common variant in people of European ancestry, present in roughly 40 to 50%, but appears less frequently in African, East Asian, and Hispanic populations. As a practical matter, SurVaxM is only eligible for HLA-A*02:01-positive patients, which cuts the addressable population by roughly half and complicates enrollment across ethnically diverse trial sites. The NCT02455557 Phase 2a trial required HLA-A*02:01 positivity for enrollment [1][3]. The peptide is chemically linked to keyhole limpet hemocyanin (KLH), a large protein from a Pacific mollusk that acts as a red flag to alert the immune system. The vaccine is delivered with GM-CSF (sargramostim) and Montanide adjuvant to recruit dendritic cells and amplify the response. The goal: generate CD8+ killer T cells that recognize survivin-derived peptides on tumor cells and destroy them [1]. The expression case for targeting survivin is strong. Whether a peptide vaccine can generate durable, tumor-penetrating T-cell responses in immunologically 'cold' cancers like GBM is the open question. 'Cold' here means tumors that physically exclude immune cells and suppress the ones that do infiltrate, so that even T cells trained by a vaccine may never reach or effectively attack the tumor.

The lead study, NCT02455557, is a single-arm Phase 2a trial in HLA-A*02:01-positive patients with newly diagnosed glioblastoma. Enrolled patients (n=64) received the Stupp regimen (the standard six-week concurrent radiation plus daily temozolomide protocol established in 2005) followed by SurVaxM vaccine during maintenance. The primary endpoint was progression-free survival, with overall survival and immune correlates as secondary endpoints. Roswell Park Comprehensive Cancer Center sponsored and ran the study [2][3]. Published results reported median PFS of 11.4 months and median OS of 25.9 months, favorable relative to the ~14.6-month median OS with the original Stupp regimen [3][9]. Important caveat on the benchmark: the modern standard of care for newly diagnosed GBM now includes tumor treating fields (TTFields, marketed as Optune), which extended median OS to about 20.9 months in the EF-14 randomized trial [12]. The 25.9-month SurVaxM Phase 2a result therefore sits closer to contemporary SOC than a comparison to the 2005 Stupp regimen implies, and investors evaluating the clinical bar should keep the TTFields-inclusive benchmark in mind. Immune correlates showed anti-survivin antibody and T-cell responses in the majority of vaccinated patients [1][3]. MGMT methylation status is a critical variable when interpreting single-arm GBM trials. MGMT is a DNA repair enzyme; when its gene is silenced by methylation (in about 40 to 45% of newly diagnosed GBM), temozolomide is far more effective and baseline median OS extends toward 22 to 25 months on Stupp alone. A single-arm trial that over-enrolls methylated patients will look better than it will replicate in a randomized setting. FDA guidance for single-arm GBM trials essentially requires MGMT stratification. The Ahluwalia 2023 paper reports MGMT status for the cohort, and the OS benefit appears to hold across strata, but this remains a caveat until randomized data arrive [3]. The design limitation of no randomized control in NCT02455557 is being addressed. SURVIVE (NCT05163080), an ongoing MimiVax-sponsored Phase 2b, randomizes patients with newly diagnosed GBM to SurVaxM plus SOC versus placebo plus SOC, with overall survival as the primary endpoint and a target enrollment of approximately 247 patients across 11 sites [13]. This is the trial that matters for regulatory purposes.

Our model estimates a 7% chance this drug is eventually approved. It starts from the historical base rate for Phase 2 drugs in this area (about 13%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by a non-randomized design and its light or open-label blinding; it is held back by the sponsor's thin or weak approval record and weak or limited earlier-phase results. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk is the biggest. Single-arm Phase 2 survival results in GBM have a decades-long history of collapsing when placed against a randomized control. Rindopepimut is the closest analog: a peptide vaccine with clean single-arm Phase 2 data that showed no benefit in ACT IV, forcing Celldex to discontinue the program in 2016 [11]. Nivolumab and pembrolizumab both failed randomized Phase 3 trials in GBM despite compelling preclinical rationale. The tumor microenvironment in glioblastoma is heavily immunosuppressive, with tumor-associated macrophages, regulatory T cells, and physical barriers to T-cell trafficking that a peripheral vaccine may struggle to overcome. The SURVIVE Phase 2b readout will resolve much of this uncertainty [13]. Safety risk appears low. Across the reported studies, SurVaxM has been well tolerated, with injection-site reactions and mild systemic symptoms the most common events [1][3]. Survivin is expressed at low levels in some proliferating normal tissues, including hematopoietic precursors and thymocytes, but no meaningful on-target toxicity has surfaced across the dosed population. That is a genuine strength going into a larger trial. Execution risk sits with MimiVax. As a small private developer, running Phase 2b/3 in newly diagnosed GBM requires significant capital, a partnership with a larger sponsor, or non-dilutive funding. Trial initiation timing, enrollment pace across multiple centers, and central immune monitoring capacity all matter. HLA-A*02:01 eligibility screening adds an operational layer and slows enrollment. Competitive risk is meaningful and shifting. DCVax-L (Northwest Biotherapeutics), an autologous dendritic cell vaccine, reported positive Phase 3 results in JAMA Oncology in 2022 and submitted a Marketing Authorization Application to the UK MHRA in December 2023 under a 150-day priority review pathway, with a decision expected in the 2025-2026 window [14][15]. If approved, DCVax-L would become the first active immunotherapy commercially available for GBM in a major market, though not in the US, where an FDA submission has not been announced. DCVax-L's mechanism (patient-specific autologous dendritic cells pulsed with tumor lysate) differs materially from SurVaxM's off-the-shelf synthetic peptide, with implications for manufacturing complexity, cost of goods, and scalability. A first-mover approval for DCVax-L would validate the therapeutic vaccine category in GBM but could also complicate SURVIVE enrollment (patients or investigators may prefer an approved option to a placebo-controlled trial). Commercial risk is moderate. GBM has clear unmet need. Temozolomide plus TTFields dominates current standard of care, and payers would cover a vaccine that demonstrably extends survival. HLA-A*02:01 restriction caps the addressable population at roughly 40 to 50% of Caucasian GBM patients and less in other groups, meaningfully constraining peak revenue potential. Pricing pressure would come from the modest patient population and single-course dosing profile.

Worth watching, with a specific set of data points that would move it from speculation to signal. What would matter most, in order: (1) SURVIVE Phase 2b topline readout (NCT05163080), the near-term catalyst that will pull the PoS band materially in either direction [13], (2) updated overall survival data from the Phase 2a study showing durable tails beyond three years, the part most likely to survive statistical scrutiny, (3) full results from the SurVaxM plus pembrolizumab recurrent GBM trial (NCT04013672), where checkpoint synergy would strengthen the mechanism story, (4) any partnership or financing announcement by MimiVax that de-risks execution of a Phase 3 registration trial, and (5) the UK MHRA decision on DCVax-L, which will reshape the competitive landscape in the same indication. The next serious inflection point is the SURVIVE readout, followed by a Phase 3 registration trial if SURVIVE is positive. In the interim, check ASCO and Society for Neuro-Oncology (SNO) meeting abstracts each year for updated Phase 2a survival curves. If MimiVax announces a partnership with a large oncology developer, the trajectory changes materially. Absent that, this is a small-cap thesis with binary Phase 2b/3 risk against a graveyard of failed GBM trials, and an addressable market structurally constrained by HLA restriction.